Treatment of First Episodes of Genital Herpes Simplex Virus Infection with Oral Acyclovir

Bryson, Yvonne J.; Dillon, Maryanne; Lovett, Michael; Acuña, G; Taylor, Stephen P.; Cherry, James D.; Johnson, Betsy; Wiesmeier, E; Growdon, William A.; Creagh-Kirk, Terri; Keeney, Ronald E.

doi:10.1097/00006254-198309000-00019

Cited by 49 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…challenge than that with gD2t when challenge virus replication in the vagina and the latent viral load in DRG were measured. Virus shedding and latent virus in DRG of mice are likely to be better predictors than survival for the efficacy of HSV-2 vaccines in humans, since humans shed virus in the genital tract and genital lesions are associated with higher genital viral loads in humans (44,45) and mice (46).…”

Section: Discussionmentioning

confidence: 99%

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2

Wang

Goodman

et al. 2016

J Virol

View full text Add to dashboard Cite

G enital herpes simplex is one of the most prevalent sexually transmitted diseases. In 2012, more than 417 million persons worldwide were reported to be infected with herpes simplex virus 2 (HSV-2), with more than 19.2 million new persons infected in that year alone (1). While HSV-2 disease is mild in most cases, infection can be severe and life threatening in immunocompromised patients and neonates. In addition, genital herpes increases the risk of acquisition of HIV infection 3-fold (2). While HSV-2 traditionally has been the principal cause of genital herpes, more recent studies have shown that HSV-1 may be replacing HSV-2 as the most frequent cause of genital herpes in the United States (3, 4). While both HSV-1 and HSV-2 cause primary and recurrent genital herpes, genital recurrences are much more frequent with HSV-2 than with HSV-1 (5).HSV-2 infects epithelial cells in the vaginal mucosa, replicates in the cells, and enters the nerve endings innervating the mucosa. Viral capsids travel retrograde in axons to the cell body in sensory ganglia, where HSV establishes a latent infection in the nuclei of neurons. Latent HSV can be reactivated by multiple stimuli, such as stress, fever, and exposure to UV light. Viral capsids travel anterograde from the ganglion down the axons to the mucosa, where the virus replicates and is shed in the presence or absence of symptomatic genital lesions. This allows the virus to spread to unin- Citation Wang K, Goodman KN, Li DY, Raffeld M, Chavez M, Cohen JI. 2016. A herpes simplex virus 2 (HSV-2) gD mutant impaired for neural tropism is superior to an HSV-2 gD subunit vaccine to protect animals from challenge with HSV-2.

show abstract

Section: Discussionmentioning

confidence: 99%

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2

Wang

Goodman

et al. 2016

J Virol

View full text Add to dashboard Cite

show abstract

“…For genital herpes, controlled clinical trials have shown that acyclovir can decrease the time required for patients to become culture-negative, decrease the time to complete healing, and reduce the incidence of complications which are particularly distressing (Bryson et et., 1983;.…”

Section: Herpes Simp/ex Virusmentioning

confidence: 99%

Progress in the Clinical Management of Herpesvirus Infections

Griffiths

1995

Antivir Chem Chemother

View full text Add to dashboard Cite

SummaryAntiviral drug discovery has produced a series of drugs active against herpesviruses in vitro. Several of these are now licensed and/or have been used in clinical practice. This article reviews the mechanisms· of action of acyclovir, ganciclovir, penciclovir, sorivudine and foscarnet, the development of resistance to these drugs and their pharmacokinetic and cellular toxicities. Based upon the natural histories of HSV, VZV and CMV, treatment objectives for each virus are discussed and the performance of each drug matched against these objectives. Overall, it is concluded that the perfect drug for treating herpesviruses does not exist, but that significant progress has been made towards controlling several herpesvirus diseases. It.is suggested that further progress will require not just improved drug discovery programmes, but also an understanding of different pathogeneses and an appreciation by practising physicians that antiviral drugs must be given early in the infectious process to achieve the best results.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Patients can be divided into those with true primary infection and those with pre-existing HSV antibody, who have what is termed first episode, non-primary or initial infection (Nahmias et al, 1981 ;Bryson et al, 1983;Straus et al, 1985). Approximately 40 ~ of patients with their first clinically apparent episode of genital disease due to HSV-2 have pre-existing HSV antibody (Bryson et al, 1983;Reeves et al, 1981 ;Corey et al, 1983). These patients appear to have milder primary infection than those with true primary HSV-2 infections (Bryson et al, 1983 ;Corey et al, 1983;Whitley, 1985), although the proportion of patients who remain asymptomatic or develop such mild symptoms that they do not seek medical attention is unknown.…”

Section: Introductionmentioning

confidence: 99%

“…Approximately 40 ~ of patients with their first clinically apparent episode of genital disease due to HSV-2 have pre-existing HSV antibody (Bryson et al, 1983;Reeves et al, 1981 ;Corey et al, 1983). These patients appear to have milder primary infection than those with true primary HSV-2 infections (Bryson et al, 1983 ;Corey et al, 1983;Whitley, 1985), although the proportion of patients who remain asymptomatic or develop such mild symptoms that they do not seek medical attention is unknown. A large proportion of HSV-2-infected patients are unaware that they have been infected (Mertz et al, 1985;Prober et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Serological Outcome of Genital Herpes Simplex Virus (HSV) Type 2 Inoculation following Oral HSV Type 1 Infection in Guinea-pigs

Bernstein

Lee

Echler

et al. 1989

Journal of General Virology

View full text Add to dashboard Cite

Treatment of First Episodes of Genital Herpes Simplex Virus Infection with Oral Acyclovir

Cited by 49 publications

References 0 publications

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2

A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2

Progress in the Clinical Management of Herpesvirus Infections

Clinical and Serological Outcome of Genital Herpes Simplex Virus (HSV) Type 2 Inoculation following Oral HSV Type 1 Infection in Guinea-pigs

Contact Info

Product

Resources

About